Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 5385  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (2,563 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References
   Article Figures

 Article Access Statistics
    Viewed218    
    Printed0    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
LETTER TO EDITOR
Year : 2021  |  Volume : 69  |  Issue : 4  |  Page : 1060-1062

Extra-Ventricular C11orf95-RELA Fusion Positive Anaplastic Ependymoma with Divergent Histological and Immunohistochemical Features: Report of a Rare Case


Department of Pathology and Neurosurgery, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

Date of Submission21-Dec-2017
Date of Decision14-Mar-2018
Date of Acceptance03-May-2020
Date of Web Publication2-Sep-2021

Correspondence Address:
Suvendu Purkait
Department of Pathology, All India Institute of Medical Sciences, Bhubaneswar, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.325311

Rights and Permissions



How to cite this article:
Purkait S, Nayak M, Patnaik A, Patra S, Malgulwar PB. Extra-Ventricular C11orf95-RELA Fusion Positive Anaplastic Ependymoma with Divergent Histological and Immunohistochemical Features: Report of a Rare Case. Neurol India 2021;69:1060-2

How to cite this URL:
Purkait S, Nayak M, Patnaik A, Patra S, Malgulwar PB. Extra-Ventricular C11orf95-RELA Fusion Positive Anaplastic Ependymoma with Divergent Histological and Immunohistochemical Features: Report of a Rare Case. Neurol India [serial online] 2021 [cited 2021 Sep 25];69:1060-2. Available from: https://www.neurologyindia.com/text.asp?2021/69/4/1060/325311




Sir,

Ependymomas commonly involve the ventricular surfaces and central canal of the brain and spinal cord. The occurrence of ependymomas in extra-ventricular cortical location is relatively rare.[1] Further, only occasional cases of ependymoma with divergent histomorphological features have been reported.[2],[3] Amongst various genetic alterations described in ependymal tumors, RELA fusion appeared to be most important for the supratentorial tumors and consider as a separate entity in the recent World Health Organization (WHO) classification.[1] In this report, a case of pediatric extra-ventricular cortical anaplastic ependymoma with distinct but unusual histological features and molecular profile is highlighted.

A 7-year-old girl child presented in the neurosurgery outpatient department (OPD) with a complaint of headache and intermittent vomiting for 1 month along with right-sided weakness for 15 days. Computed tomography (CT) scan revealed a well-circumscribed, heterogeneously enhancing, largely expansile, a solid-cystic lesion in the left frontoparietal region occupying a superficial cortical location close to midline with mass effect and midline shift. Although the left lateral ventricle was effaced by the tumor but the tumor was neither arising or involving it [Figure 1]a, [Figure 1]b, [Figure 1]c. The patient underwent left frontoparietal craniotomy with complete excision of the lesion. Intraoperatively the tumor was grayish red, soft, friable, highly vascular and intraaxial in nature without any connection to lateral ventricles. Postoperative CT scan showed complete removal of the tumor with minimal residual parenchymal edema [Figure 1]d. The patient developed hemiplegia on the right upper and lower limb which gradually improved to the power of grade 2/5 at the time of discharge. The patient underwent 30 cycles of radiotherapy. On follow up after 10 months of surgery, the patient was clinically stable. She could walk with a minimal limp (power on the right-side body of grade 4(+)/5. Contrast magnetic resonance imaging (MRI) showed no residual or recurrent lesion [Figure 1]e and [Figure 1]f.
Figure 1: (a-c) Contrast-enhanced CT scan showing a large expansile, heterogeneous lesion in left fronto-parietal convexity close to midline with gross mass effect and midline shift. (d) First-day post-operative CT scan showing complete removal of tumor. (e and f) Ten-month postoperative contrast MRI shows no recurrence or residual lesion

Click here to view


Histopathological examination showed a highly cellular tumor with a relatively well-defined margin. [Figure 2]a. It was highly cellular and comprising of small round cells. The cells were predominantly arranged in solid sheets with intervening thin-walled vascular channels. Occasional multilayered rosette-like structures with irregular lumen were identified [Figure 2]b. Ependymal true rosettes lined by a single layer of tumor cells were also identified in one focus [Figure 2]c. The individual tumor cells were round to polygonal with high nucleo-cytoplasmic ratio, round nucleus, coarse chromatin, and indistinct nucleoli. Brisk mitotic activity, areas of necrosis, and endothelial proliferation were noted [Figure 2]d and [Figure 2]e.
Figure 2: (a) Well-delineated tumor margin (H and E X100) (b) Multilayered rosette with an irregular shaped central lumen. Mitotic activity in cells lining the rosette (insert) (H and E × 400) (c) Ependymal true rosettes with a central lumen (H and E × 400). (d) Areas of tumor necrosis (H and E × 100) (e) High mitotic activity (H and E × 400) (f) Focal positive for GFAP (×400) (g and h) Perinuclear dot-like positivity for EMA and EBP-50 respectively (×400). (i) Focal positivity for desmin (×400). (j) High MIB-1 labeling index (×400). (k) Negative for p65RELA protein. (l) Electropherogram showing Type 1 C11orf95-RELA fusion

Click here to view


The tumor cells showed focal immunopositivity for Glial fibrillary acidic protein (GFAP). Staining for EMA and EBP-50 revealed cytoplasmic dot-like immunopositivity. INI-1 and ATRX staining were retained. Interestingly, some of the tumor cells also showed immunopositivity for desmin. The tumor cells were immunonegative for p65/RELA, p53, IDH-1. MIB-1 labeling index was high (approximately 30%).

For the detection of C11orf95–RELA type 1 and 2 fusion transcripts reverse transcription-polymerase chain reaction (RT-PCR) was done using primers as reported in an earlier study.[4] The presence of type I variant fusion was identified, which was further confirmed by Sanger sequencing [Figure 2]l. This analysis was performed on the mRNA isolated from the paraffin blocks.

Anaplastic ependymoma often lacks the apparent histological diagnostic features and mimics a malignant round cell tumor. Although extremely rare, a single tumor with morphological features of ependymoma as well as embryonal tumor with multilayered rosettes (ETMR) has been reported. Nobusawa et al.[2] described a case of anaplastic ependymoma which showed the presence of multilayered ependymoblastic rosette as well as an ependymal true rosette. Similarly, another case of divergent ependymal tumor with ependymoblastoma and anaplastic ependymoma was also reported by Ortiz J et al.[3] However, specific molecular analysis for ETMR (C19MC amplification) or ependymoma was not done in both these cases. In a study, Spence et al.[5] documented the presence of C19MC amplification/overexpression in some cases of PNET with ependymal morphological features. These indicated a subtle morphological overlap anaplastic ependymoma and ETMR which can lead to diagnostic difficulty. Although analysis for C19MC amplification was not done in the present case, it showed the presence of the C11orf95-RELA fusion gene.[1] However, immunohistochemistry for p65/RELA was negative. Discordant results between the molecular method and immunohistochemistry for identification of the RELA fusion gene has been documented by various studies, which may be minimized by using immunohistochemical analysis for both p65RELA and L1CAM together.[6] Till date, there are no recommendations regarding the method which should be used for the assessment of RELA fusion status. However, it is very important to assess the RELA fusion status in cases of supratentorial ependymomas because these group of tumors has worst prognosis as compared to their other counterparts irrespective of the degree of anaplasia.[7] Another unusual feature in the present case was focal desmin expression which may be attributable to the focal myoblastic differentiation as in cases of medullomyoblastoma.

This case is extremely rare in terms of divergent histological features and aberrant immunohistochemical expression. The use of immunohistochemical markers including GFAP, EMA EBP50, p65RELA, L1CAM, etc., in such cases give important clues towards diagnosis and thus help in the judicial use of molecular tests.

Acknowledgement

The molecular analysis for C11orf95-RELA fusion and immunohistochemistry for p65RELA were performed in the Neuropathology Laboratory, AIIMS, New Delhi. The authors are thankful to Prof. Chitra Sarkar for the same.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumors of the Central Nervous System (Revised 4th ed). Lyon: IARC; 2016.  Back to cited text no. 1
    
2.
Nobusawa S, Suzuki A, Nagaishi M, Isoda K, Ikota H, Yokoo H, et al. Anaplastic ependymoma with ependymoblastic multilayered rosettes. Hum Pathol 2013;44:2597-602.  Back to cited text no. 2
    
3.
Ortiz J, Otero A, Bengoechea O, Gonçalves J, Sousa P, Figols J, et al. Divergent ependymal tumor (ependymoblastoma/anaplastic ependymoma) of the posterior fossa: An uncommon case observed in a child. J Child Neurol 2008;23:1058-61.  Back to cited text no. 3
    
4.
Malgulwar PB, Nambirajan A, Pathak P, Faruq M, Rajeshwari M, Singh M, et al. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. J Neurooncol 2018;138:29-39.  Back to cited text no. 4
    
5.
Spence T, Sin-Chan P, Picard D, Barszczyk M, Hoss K, Lu M, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 2014;128:291-303.  Back to cited text no. 5
    
6.
Gessi M, Giagnacovo M, Modena P, Elefante G, Gianno F, Buttarelli FR, et al. Role of immunohistochemistry in the identification of supratentorial C11ORF95-RELA fused ependymoma in routine neuropathology. Am J Surg Pathol 2019;43:56-63.  Back to cited text no. 6
    
7.
Benson R, Mallick S, Julka PK, Rath GK. Molecular predictive and prognostic factors in ependymoma. Neurol India 2016;64:279-86.  Back to cited text no. 7
[PUBMED]  [Full text]  


    Figures

  [Figure 1], [Figure 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow